Navigation Links
The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by a Significant 43% in Acute Ischemic Stroke Patients Treated With Clexane(R) / Lovenox(R)

BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ -- Sanofi-aventis announced the publication of the PREVAIL (Prevention of VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial in the April 21st issue of The Lancet. The results of the trial showed that once daily administration of Clexane(R) / Lovenox(R) (enoxaparin sodium injection) 40 mg was more effective than UnFractionated Heparin (UFH) 5000 IU twice a day for the prevention of VTE in patients who suffered an acute ischemic stroke, a group of medically- ill patients at an increased risk for developing VTE.

Among medically-ill patients, stroke patients are at an increased risk for developing VTE. Without VTE prophylaxis, up to 75% of patients with hemiplegia following stroke develop Deep-Vein Thrombosis (DVT) and 20% develop Pulmonary Embolism (PE).

PREVAIL study showed a significant 43% relative risk reduction in VTE events was observed with Clexane(R) / Lovenox(R) vs. UFH for the primary efficacy endpoint, the composite of symptomatic or asymptomatic DVT, symptomatic and/or fatal PE during the treatment period (10.2 % vs. 18.1%; p= 0.0001).

Importantly, the reduction in VTE risk was also observed in patients presenting with different levels of ischemic stroke severity, without significant difference in clinically important bleedings as well.

The significant reduction of VTE risk with Clexane(R) / Lovenox(R) versus UFH was maintained when therapy was initiated within 24 hours or 24 hours-48 hours after stroke onset.

The incidence of the composite of symptomatic intracranial and major extracranial haemorrhage was small with no difference between groups (enoxaparin 1.3%, UFH 0.7%; p=0.2275). No difference was observed for symptomatic intracranial haemorrhage betwe
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
3. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
4. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
5. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
8. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
9. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:5/21/2013)... May 21, 2013  Lehigh Valley Health Network has ... devices, adding to its existing arsenal of five ... up residence within the network, LVHN is now deploying ... proactively combat superbugs and provide the best possible patient ... Ultraviolet Disinfector, TRU-D – the signature product of ...
(Date:5/21/2013)... 21, 2013  Healthcare organizations expanding into emerging markets ... , India and ... no shortcuts.  This is proving particularly challenging, considering the ... must change the dialogue around BRIC, as it is ... and building regional partnerships to build a sustainable business. ...
(Date:5/21/2013)... SAN DIEGO , May 21, 2013 /PRNewswire/ ... from a secondary analysis of its double-blind, randomized, ... CERE-120 is a gene therapy product designed to ... This exploratory analysis identified a more robust response ... years prior to treatment relative to those diagnosed ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... Graymark Healthcare, Inc. (NASDAQ: GRMH ), the ... innovator in comprehensive care for obstructive sleep apnea (OSA), reported ... split, which will be effective after the close of the ... stock split will automatically convert all shares of the company,s ...
... May 25, 2011 FUJIFILM Medical Systems U.S.A., Inc. ... commercial availability of the FDR D-EVO™ Wireless. This new ... will deliver Fujifilm,s renowned image quality in a ... positioning in a wider variety of imaging applications. The ...
Cached Medicine Technology:Graymark Announces 1-for-4 Reverse Stock Split 2FUJIFILM's FDR D-EVO™ Wireless Now Available in the U.S. 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 Mecklenburg EMS ... will hold a free Community Wellness Fair to educate ... The fair will be held on Wednesday, May 22, 2013 ... City YMCA (8100 Old Mallard Creek Road, Charlotte, NC ... Heart Association and the Mecklenburg County Department of ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Diversity Focus, ... working environments for all residents in the Creative Corridor ... Community Survey at a news conference on Thursday, May ... benchmark study, conducted in 2008. , The ... to lead and support efforts that attract, nurture and ...
(Date:5/21/2013)... studying the roles two proteins, thrombospondin-1 and prosaposin, ... team has identified a five-amino acid fragment of ... models of prostate, breast and lung cancer. The ... block metastasis in a variety of cancers. ... PhD, at Boston Children,s Hospital, Vivek Mittal, PhD, ...
(Date:5/21/2013)... The nation’s first trial involving a ... its conclusion in Washington state court, Bernstein Liebhard LLP ... an attorney for the Plaintiffs compared Intuitive Surgical to ... sales and services for its customers. Intuitive ... of surgeons, to keep control of hospitals and keep ...
Breaking Medicine News(10 mins):Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4
... for aggressive form of childhood disease, study says , , ... may have identified a subtype of T-lymphoblastic leukemia (T-ALL) ... chemotherapy. , Approximately 20 percent of children ... that cure others with the disease, and doctors had ...
... by the economic downturn CHICAGO, Jan. 14 The ... its 2008 Economic Impact Survey. The results reveal ... from the current economic downturn.Almost all cosmetic surgeons (95.9%) ... and about eight in ten (79.3%) cosmetic surgeons have ...
... Enrollment in Private Fee-for-Service Plans Significantly Contributed to ... HealthLeaders-InterStudy NASHVILLE, Tenn., Jan. 14 ... intelligence, reports that from January 2008 to July ... to more than 9.9 million members, an increase ...
... successful market test, Uno Chicago Grill(R) will offer its ... casual dining chain to offer a gluten-free pizza and ... celiac disease, which affects approximately one percent of the ... community during the northeastern market test prompted the company ...
... Your Diet a Makeover and Whittle Your Waist Without ... holiday period of overindulging, it,s no surprise that weight ... New Year,s resolutions. Arnold is pleased to introduce the ... dieters lower caloric intake without depriving themselves. The plan ...
... Jan. 14 Celebrating ,Cones for Kids,28th year, Friendly ... to benefit local Easter Seals Camp programs. The 2009 ... approximately 28 Easter Seals,Camp Friendly,s Program locations. , ... been a winter tradition up-and-down the,East Coast. Each ...
Cached Medicine News:Health News:Hard-to-Treat Leukemia Cell Subtype Identified 2Health News:Wrinkles on the Rise Due to the Economy 2Health News:Medicare Advantage Membership Increased by One Million Between January and July 2008 2Health News:Medicare Advantage Membership Increased by One Million Between January and July 2008 3Health News:Uno Chicago Grill(R) Rolls Out Gluten-Free Pizza Nationally 2Health News:Photos: Bring Back the Bread in Your Diet With Arnold(R) Select(TM) Sandwich Thins(TM) and Bakery Light(TM) Breads 2Health News:Photos: Bring Back the Bread in Your Diet With Arnold(R) Select(TM) Sandwich Thins(TM) and Bakery Light(TM) Breads 3Health News:Easter Seals & Friendly's Announce New focus for 28-Year Fundraising Campaign 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: